Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
Why Bluebird Bio Stock Is Taking Flight Today
12:36pm, Wednesday, 19'th Jul 2023
A Bank of America analyst upgraded the shares from neutral to buy. Bluebird's strong prospects in sickle cell disease were the main reason for the upgrade.
Down 51% in 2023, Here's Why Bluebird Bio Stock Could Soon Double, Says Wall Street
10:15am, Friday, 30'th Jun 2023
Bluebird is waiting to hear back from regulators about approval of its latest medicine. Commercializing its last two therapies wasn't enough to make it profitable.
Is Bluebird Bio Stock a Buy Now?
07:45am, Thursday, 29'th Jun 2023
Bluebird's approved treatments still are not generating much by way of sales. The company's next candidate would help substantially improve Bluebird's prospects.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Wednesday, 28'th Jun 2023
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
bluebird's (BLUE) Gene Therapy for SCD Gets Priority Review
02:52pm, Thursday, 22'nd Jun 2023
bluebird's (BLUE) gene therapy lovotibeglogene autotemcel gets Priority Review in the United States for sickle cell disease.
bluebird bio shares positioned to pop ‘significantly higher' as FDA accepts sickle cell therapy application
12:35pm, Wednesday, 21'st Jun 2023
The acceptance of bluebird bio's Biologics License Application (BLA) for its gene therapy lovotibeglogene autotemcel (lovo-cel) targeting sickle cell disease patients for priority review by the US Foo
Baird analysts unfazed by bluebird bio short sellers
11:59am, Friday, 02'nd Jun 2023
Earlier this week, Grizzy Research released a short report on gene therapy company bluebird bio, citing concerns about the company's addressable market sales and share dilution. Analysts at Baird ar
Tech Titans Aren't The Only Game In Town, Consider Biotech And, Yes, Financials
09:08pm, Sunday, 14'th May 2023
The Regional Bank Fiasco is a classic “Baby with the Bathwater” scenario. Rising rates are great for Insurance companies and “hidden banks”.
bluebird (BLUE) Posts Q1 Earnings, Focuses on Zynteglo, Skysona
01:41pm, Wednesday, 10'th May 2023
bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.
Bluebird Bio (BLUE) Q1 Earnings Surpass Estimates
09:57am, Tuesday, 09'th May 2023
Bluebird Bio (BLUE) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.54 per share. This compares to loss of $1.66 per share a year ago.
May MDA Breakout Stocks/ETFs Week 18: High-Frequency Gainers To Give You An Edge
06:11am, Sunday, 30'th Apr 2023
Two new Breakout Stocks for Week 18 with better than 10% short-term upside, ETF updates and two Dow 30 Picks. Average cumulative returns for 2023 are +58.9% YTD. Negative MG Signal continues, but peak
Why Is Bluebird Bio (BLUE) Stock Up 17% Today?
02:39pm, Friday, 28'th Apr 2023
Curative gene therapy specialist Bluebird Bio (NASDAQ: BLUE ) popped up strongly amid a broadly positive Friday on Wall Street. Primarily, the enthusiasm centers on JPMorgan Chase's Eric Joseph, who i
Why Is Bluebird (BLUE) Up 17.2% Since Last Earnings Report?
12:56pm, Friday, 28'th Apr 2023
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?
5 Top Penny Stocks To Buy According To Analysts, Targets Up To 165%
11:41am, Friday, 28'th Apr 2023
Analysts like these penny stocks but are they worth the risk?
Should Investors Buy the Dip With Bluebird Bio Stock?
10:15am, Thursday, 06'th Apr 2023
Bluebird Bio's stock is getting punished in the bear market. The business should start to bring in a lot more revenue soon.
